http://www.medpagetoday.com/Surgery/Gen ... com&mu_id=
Giving erythropoiesis-stimulating agents (ESAs) after traumatic brain injury (TBI) may improve survival without increasing comorbidities, researchers found.
In animal models, ESAs given after TBI offered neuroprotective effects by decreasing secondary neuronal damage and improving neurological outcomes. Also, Talving and colleagues had conducted an earlier retrospective analysis of 89 TBI patients given ESAs and found a significant survival benefit.
Talving and colleagues explained that in TBI, ESAs may mediate anti-inflammatory and anti-apoptotic responses, and also may enhance angiogenic properties by recruiting endothelial progenitor cells in brain tissue.
Perhaps during an acute MS relapse, this would work? Anti-inflammatory, anti-apoptotic, and enhancing angiogenesis might all be beneficial in a CCSVI model of MS, or even an autoimmune model.